Annals of Oncology Advance Access published online on November 1, 2006
Annals of Oncology, doi:10.1093/annonc/mdl393
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Department of Hematology and Oncology, Graduate School of Medicine, University of Tokyo, Japan
* To whom correspondence should be addressed. Background: Late-onset neutropenia (LON) has been reported following rituximab-containing chemotherapy. Its incidence and risk factors, however, have not been extensively studied. Patients and methods: We retrospectively reviewed the medical records of 107 patients treated with rituximab-containing chemotherapy as a primary treatment of CD20-positive B-cell lymphomas and identified cases with LON as defined by the neutrophil count of Results: With a median follow-up of 411 days, 23 patients developed LON out of the 107 at a median of 106 days after the last chemotherapy. Cumulative incidence of LON among the total patients was 24.9%. The median neutrophil count nadir was 0.61 x 109/l. The LON episodes were generally self-limited, and filgrastim was administered in one patient. Including this patient, there were no serious infectious episodes in the cases with LON. In multivariate analysis, intensive chemotherapy regimens including high-dose therapy followed by autologous hematopoietic stem cell transplantation (ASCT) and high-dose methotrexate-containing regimens without ASCT were a risk factor for LON. Conclusion: This study suggests that LON is a frequent complication of rituximab-containing intensive chemotherapy.
Received August 1, 2006
Revised September 12, 2006
Accepted September 14, 2006
original article
A high incidence of late-onset neutropenia following rituximab-containing chemotherapy as a primary treatment of CD20-positive B-cell lymphoma: a single-institution study
E. Nitta 1 
, K. Izutsu 1 , T. Sato 1, Y. Ota 2, K. Takeuchi 3, A. Kamijo 4, K. Takahashi 4, K. Oshima 1, Y. Kanda 1, S. Chiba 1, T. Motokura 1, and M. Kurokawa 1 *
2 Department of Pathology, Toranomon Hospital, Tokyo, Japan
3 Department of Pathology, Cancer Institute of Japanese Foundation for Cancer Research, Tokyo, Japan
4 Department of Transfusion Medicine and Immunohematology, Graduate School of Medicine, University of Tokyo, Japan
M. Kurokawa, E-mail: kurokawa-tky{at}umin.ac.jp
Abstract 
1.0 x 109/l without an apparent cause after the recovery of neutrophil count following completion of the intended chemotherapy.These authors contributed equally to this work.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  Y. L. Kasamon, R. J. Jones, R. A. Brodsky, E. J. Fuchs, W. Matsui, L. Luznik, J. D. Powell, A. L. Blackford, A. Goodrich, C. D. Gocke, et al. Immunologic recovery following autologous stem-cell transplantation with pre- and posttransplantation rituximab for low-grade or mantle cell lymphoma Ann. Onc., October 30, 2009; (2009) mdp484v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. K. Gopal, J. G. Rajendran, T. A. Gooley, J. M. Pagel, D. R. Fisher, S. H. Petersdorf, D. G. Maloney, J. F. Eary, F. R. Appelbaum, and O. W. Press High-Dose [131I]Tositumomab (anti-CD20) Radioimmunotherapy and Autologous Hematopoietic Stem-Cell Transplantation for Adults >= 60 Years Old With Relapsed or Refractory B-Cell Lymphoma J. Clin. Oncol., April 10, 2007; 25(11): 1396 - 1402. [Abstract] [Full Text] [PDF]
|
|